Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial

202241 citationsJournal Articlehybrid Open Access

Authors

Christina Brennan · Feinstein Institute for Medical Research

Sandeep Nadella · Donald & Barbara Zucker School of Medicine at Hofstra/Northwell

Xiang Zhao · Cold Spring Harbor Laboratory

Richard Dima · Northwell Health

Nicole Jordan–Martin · New York City Health and Hospitals Corporation

Breanna R. Demestichas · Cold Spring Harbor Laboratory

Sam O. Kleeman

Abstract

Famotidine was safe and well tolerated in outpatients with mild to moderate COVID-19. Famotidine led to earlier resolution of symptoms and inflammation without reducing anti-SARS-CoV-2 immunity. Additional randomised trials are required.

Topics & Keywords

Long-Term Effects of COVID-19 COVID-19 and Mental Health COVID-19 Clinical Research Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Gut

Volume 71, Issue 5, pp. 879-888

DOI: 10.1136/gutjnl-2022-326952

Field-Weighted Citation Impact: 4.86